This episode, covers the highlights on gastroesophageal, gastric and gastroesophageal junction (GEJ) cancer from ASCO GI 2023. Dr Nataliya Uboha (University of Wisconsin, USA) and Dr Efrat Dotan(Fox Chase Cancer Center, USA) discuss a number of key abstracts from the meeting and their implications for clinical practice. The experts start by covering a number of metastatic studies. First of all, they discuss SPOTLIGHT, a study which investigated the novel agent zolbetuximab as first line treatment in patients with claudin-18.2+/HER2 locally advanced unresectable or metastatic gastroesophageal cancer. Next they discuss Rationale 305, a study that looked at the activity of tislelizumab in combination with chemotherapy versus chemotherapy alone in patients with PD-L1 positive tumours. They also discussed the three-year follow up results from CheckMate 649, looking at nivolumab plus chemotherapy vs chemotherapy alone as first-line treatment for advanced gastroesophageal cancer. The discussion then moves on to INTEGRATE IIa, a study comparing regorafenib with placebo in refractory advanced gastroesophageal cancer.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related